The use of insulin glargine 300 lU/ml (Toujeo SoloStar®) in real clinical practice
- Authors: Antsiferov M.B1
-
Affiliations:
- SBHCI “Endocrinological Dispensary" of Moscow Healthcare Department
- Issue: No 16 (2017)
- Pages: 26-30
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/289986
- ID: 289986
Cite item
Open Access
Access granted
Abstract
The article presents the results of clinical studies, including real-world data trials, on a new analogue of long-acting insulin glargine 300 IU/ml (Toujeo SoloStar®) in patients with type 2 diabetes mellitus. Increase in glargine concentration per unit volume with the formation of a small-volume subcutaneous depot led to a change in the pharmacokinetic properties of the drug: glargine 300 IU/ml compared with glargine 100 IU/ml is more slowly released from the subcutaneous fat depot, which provides more regular and long-acting effect. That led to a change in properties of the drug, which is clinically manifested in the form of achieving comparable glycemic control with less risk of hypoglycemia and less pronounced influence on body weight compared with insulin glargine 100 U/ml.
Full Text
About the authors
M. B Antsiferov
SBHCI “Endocrinological Dispensary" of Moscow Healthcare DepartmentMD, Prof., Chief Physician
References
- International Diabetes Federation (IDF). IDF Diabetes Atlas 7th ed. idf.org. 2015.
- Inzucchi S.E. Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., Peters A.L., Tsapas A., Wender R., Matthews D.R. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140-49.
- Дедов И.И., Шестакова М.В., Майоров А.Ю. Алгоритмы специализированной медицинской помощи больным сахарным диабетом (8-й выпуск). Сахарный диабет. 2017;20(№1S).
- Riddle M.C., Bolli G.B., Ziemen M., Muehlen-Bartmer I., Bizet F., Home PD. EDITION 1 Study Investigators. New Insulin Glargine 300 Units/ mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1). Diabetes Care. 2014;37(10):2755-62.
- Yki-Järvinen H., Bergenstal R., Ziemen M., Wardecki M., Muehlen-Bartmer I., Boelle E., Riddle M.C. EDITION 2 Study Investigators. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2). Diabetes Care. 2014;37(12):3235-43.
- Bolli G.B., Riddle M.C., Bergenstal R.M., Ziemen M., Sestakauskas K., Goyeau H., Home PD. On behalf of the EDITION 3 study investigators. et al. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes. Metab. 2015;17(4):386-94.
- Sherman R.E., Anderson S.A., Dal Pan G.J., Gray G.W., Gross T, Hunter N.L., LaVange L., Marinac-Dabic D., Marks PW., Robb M.A., Shuren J., Temple R., Woodcock J., Yue L.Q., Califf R.M. Real-World Evidence - What Is It and What Can It Tell Us? N. Engl. J. Med. 2016;375(23):2293-97.
- Wong H., et al. Effect of insulin insulin glargine 300 units/ml and glargine 100 units/ml on clinical outcomes among insulin-naive patients with type 2 diabetes: a medical chart-review study in the US. 2016.
- Tong L., еt al. Effect of switching to insulin glargine 300 u/ml on clinical outcomes in patients with type 2 diabetes: a medical chart-review study in the US. 2016
- Ritzel R., Roussel R., Bolli G.B., Vinet L., Brulle-Wohlhueter C., Glezer S., Yki-Järvinen H. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ ml in people with type 2 diabetes. Diabetes Obes. Metab. 2015;17(9):859-67.
- Zhou F.L., et al. Lower risk of hypoglycemia after switch to insulin glargine 300 U/ML (GLA-300) vs other basal insulins in patients with type 2 diabetes (T2D) on basal insulin in real-world clinical settings (Deliver 2 study). 2016.
- Zhou F.L., et al. Older Adults with Type 2 Diabetes (T2D) Experience Less Hypoglycemia when Switching to Insulin Glargine 300 U/mL (Gla-300) vs. Other Basal Insulins (DELIVER 3 Study). ADA 2017. Poster-986.
Supplementary files
